Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US to explore registry to support innovation in device-based therapy for atrial fibrillation

This article was originally published in RAJ Devices

Executive Summary

The US Food and Drug Administration is to host a think-tank meeting in April to explore whether setting up a national registry of atrial fibrillation ablation procedures and outcomes would help support, among other things, the development of medical technology for this condition1. The agency describes atrial fibrillation as a major public health problem in the US. New medical devices to image, map and systematically ablate the atria have shown promise for the restoration of sinus rhythm, but, says the FDA, the optimal technique, short- and long-term safety and durability of methods and adjunctive medical therapy, all remain “areas of concern”.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts